Equities

Beijing Chunlizhengda Medical Instruments Co Ltd

Beijing Chunlizhengda Medical Instruments Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (CNY)14.17
  • Today's Change-0.23 / -1.60%
  • Shares traded2.06m
  • 1 Year change-48.81%
  • Beta--
Data delayed at least 15 minutes, as of Nov 15 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Beijing Chunlizhengda Medical Instruments Co Ltd is a China-based company mainly engaged in the research and development (R&D), production and sales of implantable orthopedic medical devices. The Company's main products are joint prosthesis products and spine implant products. The joint prosthesis products cover four human joints: hip, knee, shoulder and elbow. The spine implant products are a full range of product combinations of spinal internal fixation systems. The Company's products are exported to Asia, South America, Africa, Oceania, Europe and other countries and regions.

  • Revenue in CNY (TTM)924.65m
  • Net income in CNY158.35m
  • Incorporated1998
  • Employees1.23k
  • Location
    Beijing Chunlizhengda Medical Instruments Co Ltd20F, Tower A, Gaohe Lanfeng MansionNo. 98, East Third Ring South RoadBEIJING 101100ChinaCHN
  • Phone+86 1 087361998
  • Fax+86 1 080561690
  • Websitehttp://www.clzd.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Getein Biotech Inc1.25bn252.99m4.37bn2.14k17.261.68--3.500.49880.49882.465.120.32411.622.91584,007.906.7313.259.8618.4567.6465.5720.7628.131.69--0.20529.88-24.8514.81-43.922.3118.446.00
Qingdao NovelBeam Technology Co Ltd413.02m124.91m4.40bn797.0035.173.43--10.661.041.043.4410.630.29620.86634.68518,221.708.8114.679.3716.6363.8562.3229.7334.159.12--0.026233.55-1.3118.58-20.1921.7110.45--
Jiangsu Bioperfectus Technologies Co Ltd394.84m-170.68m4.59bn684.00--1.40--11.62-2.91-2.916.7458.000.0970.97472.52577,244.10-4.1925.41-4.7431.2665.7063.37-43.2332.864.96--0.090330.54-92.7211.81-120.45--2.43--
TINAVI Medical Technologies Co Ltd168.49m-160.48m4.60bn339.00--3.90--27.29-0.3585-0.35850.37562.620.10751.484.73475,961.90-10.24-7.86-11.04-9.0768.6673.58-95.24-50.092.21--0.1532--34.4810.63-41.42--51.87--
Assure Tech Hangzhou Co Ltd590.49m90.50m4.80bn791.0053.040.9316--8.130.7120.7124.6540.530.10111.902.85746,504.601.5531.831.7138.9736.8765.8215.3047.868.66--0.012516.05-91.8425.18-95.3533.5178.77--
Beijing Chunlizhengda Mdicl Instr Co Ltd924.65m158.35m4.82bn1.23k34.751.94--5.210.40780.40782.417.290.26980.53812.15751,138.904.6212.535.4915.4371.0872.7617.1226.893.80--0.000321.630.575919.40-9.7221.33-8.60--
Zhejiang Gongdong Medical Techno Co Ltd1.10bn162.27m4.90bn1.67k30.172.94--4.461.031.036.9510.570.56846.554.33656,174.208.4016.359.7119.2632.4841.1914.7721.623.00--0.052138.99-33.6115.11-66.535.1427.71--
Hangzhou Ags Medtech Co Ltd590.12m271.52m4.95bn592.0018.212.15--8.393.363.367.3028.530.25453.2713.92996,828.3011.71--12.26--71.52--46.01--19.56--0.003--37.09--49.87------
Xiangyu Medical Co Ltd709.56m121.39m5.18bn1.82k42.022.56--7.300.770.774.5212.660.25961.0114.80390,085.104.4411.185.6213.1266.0366.7817.1232.691.43--0.141727.3352.4615.7281.0323.11132.76--
Hangzhou Alltest Biotech Co Ltd812.78m276.54m5.25bn1.09k18.941.32--6.463.503.5010.2650.020.1982.216.97743,626.506.7423.357.2226.8353.6958.3434.0339.0710.46--0.002229.79-77.7332.59-84.7526.1972.77--
Shanghai Sanyou Medical Co Ltd434.20m37.87m5.26bn466.00147.822.75--12.110.14320.14321.717.690.19510.61915.15931,756.402.099.422.4110.8570.7287.1510.7329.783.27--0.013516.21-29.0815.67-49.918.99-15.60--
Data as of Nov 15 2024. Currency figures normalised to Beijing Chunlizhengda Medical Instruments Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

13.01%Per cent of shares held by top holders
HolderShares% Held
China Life Asset Management Co., Ltd.as of 30 Jun 20242.48m3.13%
Rosefinch Fund Management Co., Ltd.as of 30 Jun 20242.06m2.59%
China Asset Management Co., Ltd.as of 30 Jun 20241.38m1.74%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 20241.31m1.66%
Zhong Geng Fund Management Co. , Ltd.as of 30 Jun 2024812.21k1.02%
Fidelity Management & Research (Hong Kong) Ltd.as of 30 Sep 2024586.70k0.74%
Bosera Asset Management Co., Ltd.as of 30 Jun 2024475.54k0.60%
Huatai Baoxing Fund Management Co. Ltd.as of 30 Jun 2024435.00k0.55%
HuaAn Fund Management Co., Ltd.as of 30 Jun 2024388.21k0.49%
Fidelity Management & Research Co. LLCas of 30 Sep 2024386.10k0.49%
More ▼
Data from 30 Jun 2024 - 29 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.